This is a working overview of dose range, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-06 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
==== Commercialization ==== The company announced in November 2021 that it aims to achieve mass-manufacturing in 2024 of its silicon batteries, having pouch-cell samples produced by its manufacturing partner EVE Energy sent to be tested by global car makers. The company announced in 2023 that its batteries will be commercially available in VinFast vehicles in 2025. The CEO said that the company does not plan to become a battery manufacturer or supplier, but instead plans to license its technology to major manufacturers or lease dedicated manufacturing capacity from existing suppliers, saying its silicon batteries can be manufactured using existing factories and manufacturing processes. StoreDot demonstrated its batteries in a prototype Polestar 5 sedan in 2024, however the 2025 model was not set to debut with StoreDot batteries but with batteries developed and manufactured by SK On. StoreDot batteries were still in the testing phase in October 2024 and they had not been incorporated into any upcoming vehicle platforms. StoreDot stated in 2026 it needs two more years of development in order to commercialize its product.
== Peptide nucleic acids == Peptide nucleic acid (PNA) is a nucleic acid in which natural nucleic acid has been replaced by a synthetic peptide backbone formed from N-(2-amino-ethyl)-glycine units along with sugar phosphate backbone forming in an achiral and uncharged moiety that mimics RNA or DNA oligonucleotides. PNA cannot be degraded inside living cells but it is chemically stable and resistant to hydrolytic (enzymatic) cleavage.
== In absinthe == Thujone is most commonly known for being a compound in the spirit absinthe. In the past, absinthe was thought to contain up to 260–350 mg/L thujone, but modern tests have shown this estimate to be far too high. A 2008 study of 13 pre-ban (1895–1910) bottles using gas chromatography–mass spectrometry (GC-MS) found that the bottles had between 0.5 and 48.3 mg/L and averaged 25.4 mg/L A 2005 study recreated three 1899 high-wormwood recipes and tested with GC–MS, and found that the highest contained 4.3 mg/L thujone. GC–MS testing is important in this capacity because gas chromatography alone may record an inaccurately high reading of thujone as other compounds may interfere with and add to the apparent measured amount.
Sources: en.wikipedia.org
==== Varieties ==== Koikuchi (濃口; 'thick taste'): Originating in the Kantō region, its usage eventually spread all over Japan. Over 80% of the Japanese domestic soy sauce production is of koikuchi, and can be considered the typical Japanese soy sauce. It is made from roughly equal quantities of soybean and wheat. This variety is also called kijōyu (生醤油) or namashōyu (生しょうゆ) when it is not pasteurized. Usukuchi (薄口; 'thin taste'): Almost 14% of soy sauce production is usukuchi shoyu. It is particularly popular in the Kansai region of Japan. It matures for less time than koichuchi and is both saltier and lighter in color. It is paler due to the use in its production of amazake, a sweet liquid made from fermented rice. Usukuchi is commonly used in cooking as it does not alter the color and taste of the ingredients. Tamari (たまり): Made mainly in the Chūbu region of Japan, tamari is darker in appearance and richer in flavor than koikuchi. It contains little or no wheat. Wheat-free tamari can be used by people with gluten intolerance. Tamari is more viscous than koikuchi shoyu. Of soy sauce produced in Japan, 1.5% is tamari. It is the "original" Japanese soy sauce, as its recipe is closest to the soy sauce originally introduced to Japan from China. Technically, this variety is known as miso-damari (味噌溜り), as this is the liquid that runs off miso (a soybean-based seasoning and soup base) as it matures.
Oxidation using hydrogen peroxide is often used as a low cost pyrogen destroying solution. The mechanism for this destruction is unknown, but hydrogen peroxide can easily be removed further downstream in the purification process, and is therefore a useful method of pyrogen removal. However, like acid-base hydrolysis, it is not suitable when purifying proteins.
=== Dietary supplement === In the United States, the extract for use in dietary supplements has self-affirmed generally recognized as safe (GRAS) status, as an ingredient. Supplemental use occurs in various forms, such as root powders, an additive in tea or coffee, and capsules alone or in combination with other ingredients. It is commonly used by bodybuilders or other sports participants in the belief the compound can increase testosterone levels that would improve performance. Available clinical research has found no significant effect of E. longifolia as a supplement. It is under preliminary research for erectile dysfunction, immunomodulation, and other effects. Side effects of using supplements may include nausea, abdominal discomfort, diarrhea, or headaches. Rare cases of liver injury have occurred from its use, mostly in bodybuilders. E. longifolia supplements should not be used during pregnancy. Its long-term safety over regular use has not been adequately assessed.
Sources: en.wikipedia.org
Berry steps down from the post in order to run as Green candidate in Brighton Pavilion, where current MP Caroline Lucas is standing down at the next election. 8 May – John Swinney is sworn in as Scotland's seventh first minister at a ceremony at the Court of Session in Edinburgh. Swinney appoints Kate Forbes as Scotland's Deputy First Minister. The Conservative Member of Parliament for Dover Natalie Elphicke defects to the Labour Party. The Labour whip is restored to Kate Osamor. Former England cricketer Monty Panesar quits the Workers Party of Britain a week after being unveiled as one of its general election candidates. MSs vote 43–16 to approve the Senedd Reform Bill that will see the number of members increase from 60 to 96 at the next election. 9 May – Former cabinet minister Nadhim Zahawi says he will stand down from Parliament at the next election. Natalie Elphicke apologises for past comments in support of her ex-husband, Charlie, which she made when he was convicted of sexual assault. Swinney confirms to the BBC that the SNP's strategy of using the next general election as a mandate for a second referendum on Scottish independence remains. The government announces that a ban on sex offenders in England and Wales changing their name to avoid detection will be brought in. 10 May – The Scottish Government reaffirms its wish to see the Gender Recognition Reform (Scotland) Bill enacted.
== Council of Ministers == The Council of Ministers is structured into the offices for the prime minister, the four deputy prime ministers, 22 ministries and the post of the spokesperson of the Government.
206Pb is the final step in the decay chain of 238U, the "radium series" or "uranium series". In a closed system, over time, a given mass of 238U will decay in a sequence of steps culminating in 206Pb. The production of intermediate products eventually reaches an equilibrium (though this takes a long time, as the half-life of 234U is 245,500 years). Once this stabilized system is reached, the ratio of 238U to 206Pb will steadily decrease, while the ratios of the other intermediate products to each other remain constant. Like most radioisotopes found in the radium series, 206Pb was initially named as a variation of radium, specifically radium G. It is the decay product of both 210Po (historically called radium F) by alpha decay, and the much rarer 206Tl (radium EII) by beta decay. Lead-206 has been proposed for use in fast breeder nuclear fission reactor coolant over the use of natural lead mixture (which also includes other stable lead isotopes) as a mechanism to improve neutron economy and greatly suppress unwanted production of highly radioactive byproducts.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.